Could a common antibiotic cure a parasitic skin disease?

NCT ID NCT06798402

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tests whether injecting the antibiotic ciprofloxacin directly into skin sores caused by leishmaniasis works as well as the standard treatment, sodium stibogluconate. Eighty people with one to seven sores will be randomly assigned to receive weekly injections of one drug or the other. The sores will be monitored for up to 90 days to see which treatment leads to better healing.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
ciprofloxacin (an antibiotic) and sodium stibogluconate (a standard anti-parasitic drug)
What this could lead to
If ciprofloxacin works as well as the standard treatment, it could offer a more widely available and cheaper option for treating cutaneous leishmaniasis.
What could go wrong
This is a small, early-phase trial with only 80 participants. Ciprofloxacin may not be as effective as the standard drug, and results may not apply to all types of leishmaniasis.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS LEISHMANIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Mustansiriyah University

    RECRUITING

    Baghdad, 10047, Iraq

More trials for these conditions

Other studies related to the condition(s) this trial covers.